Nuclear recoil measurements in Superheated Superconducting Granule detectors

The response of Superheated Superconducting Granule (SSG) devices to nuclear recoils has been explored by irradiating SSG detectors with a 70Me$\!$V neutron beam. In the past we have tested Al SSG and more recently, measurements have been performed with Sn and Zn detectors. The aim of the experiments was to test the sensitivity of SSG detectors to recoil energies down to a few ke$\!$V. In this paper, the preliminary results of the neutron irradiation of a SSG detector made of Sn granules 15-20$\mu$m in diameter will be discussed. For the first time, recoil energy thresholds of $\sim$1ke$\!$V have been measured.Comment: 7pages in Latex format, Preprint Bu-He 93/6 (University of Berne, Switzerland), four figures available upon request via [email protected] or [email protected]

The effects of man-marking on work intensity in small-sided soccer games

The aim of this study was to examine the effect of manipulating defensive rules: with and without man-marking (MM and NMM) on exercise intensity in 3 vs. 3 small-sided games (SSGs). Twelve adolescent soccer players (age: 16.2 ± 0.7 years; body mass: 55.7 ± 6.4 kg; body height: 1.70 ± 0.07 m) participated in this repeated measures study. Each participant performed in four different SSGs formats: 3 vs. 3 MM with and without goals and 3 vs. 3 NMM with and without goals. Each SSG lasted 3 x 4 minutes interspersed with 4 minutes passive recovery. The percentage heart rate reserve (%HRreserve) was recorded continuously during SSG and session-rating of perceived exertion (session-RPE) after the SSG. MANOVA showed that defensive rule had significant effects on intensity (F = 5.37, p < 0.01). Specifically, MM during SSG induced significantly higher %HRreserve compared to NMM (Goal: 80.5 vs. 75.7%; No goal: 80.5 vs. 76.1%; p < 0.05, effect size = 0.91-1.06), irrespective of the presence or absence of goals. However, only MM with the presence of goals induced significant higher session-RPE compared to NMM (7.1 vs. 6.0; p < 0.05, effect size = 1.36), whereas no difference in session-RPE was observed between MM and NMM (7.4 vs. 6.9; p > 0.05, effect size = 0.63) when no goals were used. Higher intra-class reliability and lower coefficient of variation values were also reported in MM as compared to NMM. This study in youth soccer players shows there is ~4.5% increase in heart rate response by using the man-marking in 3 vs. 3 SSG thus the intensity of SSG can be significantly increased when using man-marking tactics

Comparison of Generic and Proprietary Sodium Stibogluconate for the Treatment of Visceral Leishmaniasis in Kenya.

OBJECTIVE: To compare the use of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis (kala-azar). METHODS: A total of 102 patients with confirmed kala-azar were treated in a mission hospital in West Pokot region, Kenya, with sodium stibogluconate (20 mg/kg/day for 30 days)--either as Pentostam (PSM) or generic sodium stibogluconate (SSG); 51 patients were allocated alternately to each treatment group. FINDINGS: There were no significant differences in baseline demographic characteristics or disease severity, or in events during treatment. There were 3 deaths in the PSM group and 1 in the SSG group; 2 patients defaulted in each group. Only 1 out of 80 test-of-cure splenic aspirates was positive for Leishmania spp.; this patient was in the SSG group. Follow-up after > or = 6 months showed that 6 out of 58 patients had relapsed, 5 in the SSG group and 1 in the PSM group. No outcome variable was significantly different between the two groups. CONCLUSION: The availability of cheaper generic sodium stibogluconate, subject to rigid quality controls, now makes it possible for the health authorities in kala-azar endemic areas to provide treatment to many more patients in Africa

A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.

OBJECTIVE: To compare the outcome of treatment of Sudanese kala-azar patients treated under field conditions with either branded sodium stibogluconate (SSG) (Pentostam GlaxoWellcome) or generic SSG (Albert David Ltd, Calcutta, supplied by International Dispensary Association, Amsterdam). METHOD: Randomised comparison. 271 patients were treated with Pentostam and 245 with generic SSG. RESULTS: No statistically significant differences in cure rate or mortality were detected between Pentostam and generic SSG. No differences in side-effects between the two drugs were noted. The initial cure rate at the time of discharge was 93.7 and 97.6%, respectively; the death rate during treatment 5.9 and 2.4%. Six months follow up was achieved in 88.5% of the discharged patients. Two patients had died in the Pentostam group and two had died in the generic SSG group, giving a final death rate of 7.5 and 3.7%. The number of relapses in the Pentostam and generic SSG groups were 3 and 1, respectively. The final cure rates, calculated at 6 months after discharge, were 91.3% and 95.9%. CONCLUSION: No difference was observed in the performance of generic SSG compared to Pentostam for the treatment of visceral leishmaniasis in Sudan. Generic SSG can be routinely and safely used for the treatment of kala-azar. Generic SSG costs only 1/14 of the price of Pentostam. The use of generic SSG may make treatment of kala-azar affordable for national governments in Africa

A Comparison of Miltefosine and Sodium Stibogluconate for Treatment of Visceral Leishmaniasis in an Ethiopian Population with High Prevalence of HIV Infection.

BACKGROUND: Antimonials are the mainstay of visceral leishmaniasis (VL) treatment in Africa. The increasing incidence of human immunodeficiency virus (HIV) coinfection requires alternative safe and effective drug regimens. Oral miltefosine has been proven to be safe and effective in the treatment of Indian VL but has not been studied in Africa or in persons with HIV and VL coinfection. METHODS: We compared the efficacy of miltefosine and sodium stibogluconate (SSG) in the treatment of VL in persons in Ethiopia. A total of 580 men with parasitologically and/or serologically confirmed VL were randomized to receive either oral miltefosine (100 mg per day for 28 days) or intramuscular SSG (20 mg/kg per day for 30 days). RESULTS: The initial cure rate was 88% in both treatment groups. Mortality during treatment was 2% in the miltefosine group, compared with 10% in the SSG group. Initial treatment failure was 8% in the miltefosine group, compared with 1% in the SSG group. Among the 375 patients (65%) who agreed to HIV testing, HIV seroprevalence was 29%. Among patients not infected with HIV, initial cure, mortality, and initial treatment failure rates were not significantly different (94% vs. 95%, 1% vs. 3%, and 5% vs. 1% for the miltefosine and SSG groups, respectively). Initial treatment failure with miltefosine occurred in 18% of HIV-coinfected patients, compared with treatment failure in 5% of non-HIV-infected patients. At 6 months after treatment, 174 (60%) of the 290 miltefosine recipients and 189 (65%) of the 290 SSG recipients experienced cure; 30 (10%) of 290 in the miltefosine group and 7 (2%) of 290 in the SSG group experienced relapse, and the mortality rate was 6% in the miltefosine group, compared with 12% in the SSG group. HIV-infected patients had higher rates of relapse (16 [25%] of 63 patients), compared with non-HIV-infected patients (5 [5%] of 131). CONCLUSIONS: Treatment with miltefosine is equally effective as standard SSG treatment in non-HIV-infected men with VL. Among HIV-coinfected patients, miltefosine is safer but less effective than SSG

Achieving Optimal Throughput and Near-Optimal Asymptotic Delay Performance in Multi-Channel Wireless Networks with Low Complexity: A Practical Greedy Scheduling Policy

In this paper, we focus on the scheduling problem in multi-channel wireless networks, e.g., the downlink of a single cell in fourth generation (4G) OFDM-based cellular networks. Our goal is to design practical scheduling policies that can achieve provably good performance in terms of both throughput and delay, at a low complexity. While a class of $O(n^{2.5} \log n)$-complexity hybrid scheduling policies are recently developed to guarantee both rate-function delay optimality (in the many-channel many-user asymptotic regime) and throughput optimality (in the general non-asymptotic setting), their practical complexity is typically high. To address this issue, we develop a simple greedy policy called Delay-based Server-Side-Greedy (D-SSG) with a \lower complexity $2n^2+2n$, and rigorously prove that D-SSG not only achieves throughput optimality, but also guarantees near-optimal asymptotic delay performance. Specifically, we show that the rate-function attained by D-SSG for any delay-violation threshold $b$, is no smaller than the maximum achievable rate-function by any scheduling policy for threshold $b-1$. Thus, we are able to achieve a reduction in complexity (from $O(n^{2.5} \log n)$ of the hybrid policies to $2n^2 + 2n$) with a minimal drop in the delay performance. More importantly, in practice, D-SSG generally has a substantially lower complexity than the hybrid policies that typically have a large constant factor hidden in the $O(\cdot)$ notation. Finally, we conduct numerical simulations to validate our theoretical results in various scenarios. The simulation results show that D-SSG not only guarantees a near-optimal rate-function, but also empirically is virtually indistinguishable from delay-optimal policies.Comment: Accepted for publication by the IEEE/ACM Transactions on Networking, February 2014. A preliminary version of this work was presented at IEEE INFOCOM 2013, Turin, Italy, April 201